Institutional investors boosted Bristol Myers Squibb shares after strong Q3 earnings and raised 2025 guidance.

Institutional investors including Procyon Advisors, Nordea Investment Management, and MGO One Seven increased their stakes in Bristol Myers Squibb during Q3 2025. The company reported strong Q3 earnings on October 30, 2025, with $1.63 EPS, beating estimates by $0.11, and $12.22 billion in revenue, up 2.8% year-over-year. It raised its 2025 full-year EPS guidance to $6.40–$6.60. The stock traded around $56.60 on January 16, 2026, with a market cap of $115.22 billion, a 4.5% dividend yield, and a consensus "Hold" rating.